4
Changes in Ownership
Protalix BioTherapeutics, Inc. Filed Acc 0001104659-22-098951
Options or other derivatives
- VP, Research & Development acquired 250,000 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Derivatives | |||||||
| Hayon Yael VP, Research & Development | 2022-09-07 | Grant or award · Stock Options (Right to Buy) | +250,000 | 250,000 | D | ||
Loading xslF345X03/tm2225460-8_4seq1.xml…